Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.71B
Revenue (ttm)	972.89M
Net Income (ttm)	648.69M
Shares Out	n/a
EPS (ttm)	0.84
PE Ratio	8.80
Forward PE	n/a
Dividend	0.23 (6.59%)
Ex-Dividend Date	Jun 25, 2025

Volume	60,200
Average Volume	120,210
Open	3.440
Previous Close	3.430
Day's Range	3.400 - 3.440
52-Week Range	1.990 - 3.500
Beta	n/a
RSI	64.86
Earnings Date	Mar 31, 2026

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY